PACB vs WGS
PACB: Pacific Biosciences provides high-accuracy, long-read genomic sequencing solutions that enable researchers and clinicians to solve complex genetic challenges. WGS: GeneDx is a genomic intelligence platform using whole-genome sequencing and AI-powered interpretation to diagnose rare diseases, analyze cancers, and support precision medicine across clinical and research settings.
Side-by-side fundamentals
| Metric | PACB | WGS | Edge |
|---|---|---|---|
| Price as of 2026-07-30 close | $1.48 | $60.54 | |
| Market cap as of 2026-07-31 | $460M | $1.8B | |
| PEG as of 2026-07-31 | n/a | -0.30 | |
| Net margin as of 2026-07-31 | -80.3% | -17.6% | WGS higher |
| Gross margin as of 2026-07-31 | +40.3% | +69.6% | WGS higher |
| Operating margin as of 2026-07-31 | -83.3% | -16.4% | WGS higher |
| ROE as of 2026-07-31 | -488.4% | -27.5% | WGS higher |
| ROA as of 2026-07-31 | -16.1% | -15.7% | WGS higher |
| Debt / equity as of 2026-07-31 | 272.23 | 0.38 | WGS lower |
| Revenue growth (YoY) as of 2026-07-31 | +5.0% | +34.1% | WGS higher |
| Revenue CAGR (3y) SEC XBRL | -6.9% | +22.1% | WGS higher |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-31 | 2.00 | 2.01 | |
| 1-year return as of 2026-07-30 close | -0.7% | -24.2% | PACB higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.